85 related articles for article (PubMed ID: 1952963)
1. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
2. [Late phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Yamada K; Ohno R; Oguri T; Kamiya O; Yokomaku S; Kobayashi M; Nishiwaki H; Tanaka M; Inagaki J; Mitomo Y
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2447-52. PubMed ID: 1952964
[TBL] [Abstract][Full Text] [Related]
3. [Late phase II study of MST-16 (sobuzoxane) efficacy for malignant lymphoma].
Masaoka T; Kageyama T; Tatsumi N; Akasaka K; Yonezawa T; Sugiyama H; Kitani T; Yasunaga K; Horiuchi A; Nakayama S
Gan To Kagaku Ryoho; 1992 Mar; 19(3):339-47. PubMed ID: 1543360
[TBL] [Abstract][Full Text] [Related]
4. [Early phase II study of MST-16 (sobuzoxane) for breast cancer].
Tominaga T; Shimozuma K; Hasegawa K; Hayashibara K; Nakahiro K; Nakao I; Katayama K; Fukuda M; Majima H; Aoyama H
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1009-15. PubMed ID: 8210250
[TBL] [Abstract][Full Text] [Related]
5. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of MST-16].
Furue H; Niitani H; Nakao I; Hoshino A; Hasegawa K; Tsukagoshi S; Fujita H
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1287-94. PubMed ID: 2369134
[TBL] [Abstract][Full Text] [Related]
7. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
[TBL] [Abstract][Full Text] [Related]
8. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
9. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
[TBL] [Abstract][Full Text] [Related]
10. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
12. [A phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. THP Study Group].
Kimura K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):368-75. PubMed ID: 3947112
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
14. [Clinical treatment of MST-16 (Sobuzoxane) for malignant lymphoma].
Nakayama S; Yabe H; Nagai K
Gan To Kagaku Ryoho; 1991 Sep; 18(12):2179-82. PubMed ID: 1888191
[No Abstract] [Full Text] [Related]
15. Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
Ohno R; Yamada K; Hirano M; Shirakawa S; Tanaka M; Oguri T; Kodera Y; Mitomo Y; Ikeda Y; Yokomaku S
J Natl Cancer Inst; 1992 Mar; 84(6):435-8. PubMed ID: 1538420
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Oguro M; Takagi T
Gan To Kagaku Ryoho; 1982 Mar; 9(3):508-15. PubMed ID: 6764108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
